Experimental HCV Drugs
Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Sunday, 16 April 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.
Full coverage listing by topic
4/16/17
CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 18 February 2017 00:00
- Written by Liz Highleyman
AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease
- Details
- Category: HCV Treatment
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
A 2-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for chronic hepatitis C patients with severe kidney impairment, according to results from the EXPEDITION-4 study presented at the 2016 AASLD Liver Meeting last month in Boston.
Gilead and AbbVie Seek FDA Approval of Pangenotypic Hepatitis C Treatments
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 27 December 2016 00:00
- Written by Liz Highleyman
Gilead Sciences and AbbVie both announced this month that they have applied for U.S. Food and Drug Administration approval of new all-oral ribavirin-free combination regimens to treat all genotypes of hepatitis C virus (HCV). Gilead's sofosbuvir/velpatasvir/ voxilaprevir and AbbVie's glecaprevir/pibrentasvir have demonstrated high cure rates in Phase 3 clinical trials.
AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 17 November 2016 00:00
- Written by Liz Highleyman
A new 3-drug coformulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2, or 3, with sustained response rates of 86% to 100% depending on treatment duration, according to study results presented this month at the AASLD Liver Meeting in Boston. Related studies showed that the combination is also effective for retreating people who were not cured with a previous course of direct-acting antivirals (DAAs).
More Articles...
- AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C
- AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes
- AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with HCV Genotype 3
- IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6 Hepatitis C